| Primary |
| Ovulation Induction |
34.0% |
| In Vitro Fertilisation |
32.1% |
| Infertility |
15.1% |
| Infertility Female |
7.5% |
| Artificial Insemination By Partner |
3.8% |
| Assisted Fertilisation |
3.8% |
| Ovulation Disorder |
3.8% |
|
| Ovarian Hyperstimulation Syndrome |
12.5% |
| Pregnancy |
12.5% |
| Twin Pregnancy |
9.4% |
| Drug Exposure During Pregnancy |
6.3% |
| Pelvic Fluid Collection |
6.3% |
| Premature Baby |
6.3% |
| Umbilical Cord Prolapse |
6.3% |
| Abortion Spontaneous |
3.1% |
| Breast Cancer Female |
3.1% |
| Disseminated Intravascular Coagulation |
3.1% |
| Malignant Hydatidiform Mole |
3.1% |
| Malignant Melanoma Stage Ii |
3.1% |
| Metastases To Lung |
3.1% |
| Metastases To Lymph Nodes |
3.1% |
| Muscular Weakness |
3.1% |
| Pleural Effusion |
3.1% |
| Premature Rupture Of Membranes |
3.1% |
| Pyloric Stenosis |
3.1% |
| Skin Lesion |
3.1% |
| Small For Dates Baby |
3.1% |
|
| Secondary |
| In Vitro Fertilisation |
35.0% |
| Ovulation Induction |
23.2% |
| Infertility |
7.9% |
| Assisted Fertilisation |
6.4% |
| Ovarian Disorder |
5.9% |
| Luteal Phase Deficiency |
3.4% |
| Infertile Partner |
3.0% |
| Product Used For Unknown Indication |
3.0% |
| Infertility Female |
2.5% |
| Artificial Insemination By Partner |
1.5% |
| Ovarian Hyperstimulation Syndrome |
1.5% |
| Coagulopathy |
1.0% |
| Drug Use For Unknown Indication |
1.0% |
| Endometriosis |
1.0% |
| Hypothalamo-pituitary Disorders |
1.0% |
| Polycystic Ovaries |
1.0% |
| Adrenal Suppression |
0.5% |
| Anaesthesia |
0.5% |
| Anovulatory Cycle |
0.5% |
| Hypothalamo-pituitary Disorder |
0.5% |
|
| Ovarian Hyperstimulation Syndrome |
14.0% |
| White Blood Cell Count Increased |
12.3% |
| Pleural Effusion |
8.8% |
| Pregnancy |
8.8% |
| Twin Pregnancy |
8.8% |
| Weight Increased |
7.0% |
| Ectopic Pregnancy |
5.3% |
| Ovarian Torsion |
5.3% |
| Breast Cancer |
3.5% |
| Cytogenetic Abnormality |
3.5% |
| Drug Exposure During Pregnancy |
3.5% |
| Nervous System Disorder |
3.5% |
| Staphylococcal Infection |
3.5% |
| Abortion Induced |
1.8% |
| Abortion Spontaneous |
1.8% |
| Congenital Hydrocephalus |
1.8% |
| Conjoined Twins |
1.8% |
| Craniopharyngioma |
1.8% |
| Intra-abdominal Haemorrhage |
1.8% |
| Intra-uterine Death |
1.8% |
|
| Concomitant |
| In Vitro Fertilisation |
58.2% |
| Ovulation Induction |
14.9% |
| Prevention Of Premature Ovulation |
11.3% |
| Assisted Fertilisation |
4.3% |
| Infertility |
3.5% |
| Drug Exposure During Pregnancy |
2.1% |
| Endometriosis |
1.4% |
| Epilepsy |
1.4% |
| Ovarian Disorder |
1.4% |
| Hypothyroidism |
0.7% |
| Infertility Female |
0.7% |
|
| Twin Pregnancy |
12.1% |
| Maternal Exposure During Pregnancy |
9.1% |
| Abortion |
6.1% |
| Cardiovascular Insufficiency |
6.1% |
| Exposure During Pregnancy |
6.1% |
| Foetal Exposure During Pregnancy |
6.1% |
| Maternal Exposure Before Pregnancy |
6.1% |
| Ovarian Hyperstimulation Syndrome |
6.1% |
| Pallor |
6.1% |
| Pregnancy |
6.1% |
| Abortion Missed |
3.0% |
| Cardio-respiratory Distress |
3.0% |
| Cerebral Calcification |
3.0% |
| Ectopic Pregnancy |
3.0% |
| Foetal Death |
3.0% |
| Hypersensitivity |
3.0% |
| Multiple Pregnancy |
3.0% |
| Multiple Sclerosis |
3.0% |
| Nausea |
3.0% |
| Post Procedural Complication |
3.0% |
|
| Interacting |
| In Vitro Fertilisation |
100.0% |
|
| Ovarian Hyperstimulation Syndrome |
100.0% |
|
